Biology and clinical relevance of EpCAM

Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein primarily known to mediate homotypic cell contacts in epithelia tissues. Because EpCAM expression is limited to normal and malignant epithelia, it has been used as diagnostic marker for the detection of carcinoma cells in mese...

Full description

Saved in:
Bibliographic Details
Published inCell Stress Vol. 3; no. 6; pp. 165 - 180
Main Authors Keller, Laura, Werner, Stefan, Pantel, Klaus
Format Journal Article
LanguageEnglish
Published Austria Shared Science Publishers OG 21.05.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein primarily known to mediate homotypic cell contacts in epithelia tissues. Because EpCAM expression is limited to normal and malignant epithelia, it has been used as diagnostic marker for the detection of carcinoma cells in mesenchymal organs such as blood, bone marrow or lymph nodes. In particular, the detection and molecular characterization of EpCAM-positive circulating tumor cells (CTCs) in the blood of carcinoma patients has gained considerable interest over the past ten years. EpCAM is primarily considered as an adhesion molecule, but recent studies have shown diverse biological functions including regulation of cell proliferation and cancer stemness. In this review, we summarize the current knowledge on the biological properties of EpCAM with emphasis on mechanisms involved in cancer progression and discuss the clinical implications of these findings for the clinical use of EpCAM as a diagnostic marker.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Please cite this article as: Laura Keller, Stefan Werner and Klaus Pantel (2019). Biology and clinical relevance of EpCAM. Cell Stress 3(6): 165-180. doi: 10.15698/cst2019.06.188
Conflict of interest: K.P. has ongoing patent applications related to circulating tumor cells. K.P. has received honoraria from Agena, Novartis, Roche and Sanofi and research funding from European Federation of Pharmaceutical Industries and Associations (EFPIA) partners (Angle, Menarini and Servier) of the CANCER-ID programme of the European Union–EFPIA Innovative Medicines Initiative. L.K and S.W. declare no conflict of interest.
ISSN:2523-0204
2523-0204
DOI:10.15698/cst2019.06.188